Journal
CLINICAL REVIEWS IN BONE AND MINERAL METABOLISM
Volume 10, Issue 2, Pages 108-116Publisher
SPRINGER
DOI: 10.1007/s12018-011-9123-5
Keywords
Sclerostin; Sclerosteosis; van Buchem disease
Categories
Funding
- European Union [HEALTH-F22008-20199]
Ask authors/readers for more resources
In the last decade, osteocyte-produced sclerostin has emerged as a key regulator of bone remodeling. Sclerostin inhibits bone formation and may also stimulate bone resorption. Impaired sclerostin synthesis leads to generalized hyperostosis, particularly of the skull bones, in patients with sclerosteosis and van Buchem disease due to unrestrained bone formation. The synthesis of sclerostin is controlled by systemic and local factors, and aberrant sclerostin synthesis has been reported in several disorders of bone and mineral metabolism. The restricted expression of sclerostin in bone, the excellent quality of bone of patients with sclerosteosis and van Buchem disease and the lack of abnormalities in organs other than the skeleton in these patients have made sclerostin a promising target for new bone-building therapies for osteoporosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available